Intercept Pharmaceuticals (NAS:ICPT) Piotroski F-Score

: 5 (As of Today)

View and export this data going back to 2012. Start your Free Trial

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Intercept Pharmaceuticals has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Intercept Pharmaceuticals's Piotroski F-Score or its related term are showing as below:

ICPT' s Piotroski F-Score Range Over the Past 10 Years
Min: 2 Med: 3 Max: 5
Current: 5

During the past 13 years, the highest Piotroski F-Score of Intercept Pharmaceuticals was 5. The lowest was 2. And the median was 3.

Intercept Pharmaceuticals Piotroski F-Score Historical Data

The historical data trend for Intercept Pharmaceuticals's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intercept Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Piotroski F-Score

2.00

3.00

5.00

Intercept Pharmaceuticals Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Piotroski F-Score																5.00	5.00	4.00	5.00	5.00

Competitive Comparison

For the Biotechnology subindustry, Intercept Pharmaceuticals's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

Intercept Pharmaceuticals Piotroski F-Score Distribution

For the Biotechnology industry and Healthcare sector, Intercept Pharmaceuticals's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Intercept Pharmaceuticals's Piotroski F-Score falls in comparison to its industry or sector. The grey bar indicates the Piotroski F-Score's extreme value range as defined by GuruFocus.

How is the Piotroski F-Score calculated?

This Year (Mar23) TTM:

Last Year (Mar22) TTM:

Net Income was -7.528 + 267.453 + -20.825 + -32.135 = $207.0 Mil.
Cash Flow from Operations was 14.738 + -16.588 + -4.806 + -51.597 = $-58.3 Mil.
Revenue was 71.757 + 77.588 + 77.219 + 67.958 = $294.5 Mil.
Gross Profit was 71.448 + 77.164 + 77.191 + 67.736 = $293.5 Mil.
Average Total Assets from the begining of this year (Mar22)
to the end of this year (Mar23) was
(503.357 + 498.597 + 559.404 + 553.711 + 504.085) / 5 = $523.8308 Mil.
Total Assets at the begining of this year (Mar22) was $503.4 Mil.
Long-Term Debt & Capital Lease Obligation was $223.4 Mil.
Total Current Assets was $490.5 Mil.
Total Current Liabilities was $207.1 Mil.

Net Income was -11.094 + -3.632 + -36.28 + -17.284 = $-68.3 Mil.

Revenue was 68.178 + 66.64 + 68.633 + 59.146 = $262.6 Mil.
Gross Profit was 67.924 + 66.416 + 68.199 + 58.923 = $261.5 Mil.
Average Total Assets from the begining of last year (Mar21)
to the end of last year (Mar22) was
(520.111 + 523.224 + 523.074 + 527.023 + 503.357) / 5 = $519.3578 Mil.
Total Assets at the begining of last year (Mar21) was $520.1 Mil.
Long-Term Debt & Capital Lease Obligation was $724.1 Mil.
Total Current Assets was $477.4 Mil.
Total Current Liabilities was $151.0 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Intercept Pharmaceuticals's current Net Income (TTM) was 207.0. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Intercept Pharmaceuticals's current Cash Flow from Operations (TTM) was -58.3. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)	=	Net Income	/	Total Assets (Mar22)
	=	206.965	/	503.357
	=	0.41116941

ROA (Last Year)	=	Net Income	/	Total Assets (Mar21)
	=	-68.29	/	520.111
	=	-0.1312989

Intercept Pharmaceuticals's return on assets of this year was 0.41116941. Intercept Pharmaceuticals's return on assets of last year was -0.1312989. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Intercept Pharmaceuticals's current Net Income (TTM) was 207.0. Intercept Pharmaceuticals's current Cash Flow from Operations (TTM) was -58.3. ==> -58.3 <= 207.0 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar23)	=	Long-Term Debt & Capital Lease Obligation	/	Average Total Assets from Mar22 to Mar23
	=	223.352	/	523.8308
	=	0.42638195

Gearing (Last Year: Mar22)	=	Long-Term Debt & Capital Lease Obligation	/	Average Total Assets from Mar21 to Mar22
	=	724.082	/	519.3578
	=	1.39418721

Intercept Pharmaceuticals's gearing of this year was 0.42638195. Intercept Pharmaceuticals's gearing of last year was 1.39418721. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar23)	=	Total Current Assets	/	Total Current Liabilities
	=	490.457	/	207.117
	=	2.36801904

Current Ratio (Last Year: Mar22)	=	Total Current Assets	/	Total Current Liabilities
	=	477.353	/	151.036
	=	3.16052464

Intercept Pharmaceuticals's current ratio of this year was 2.36801904. Intercept Pharmaceuticals's current ratio of last year was 3.16052464. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Intercept Pharmaceuticals's number of shares in issue this year was 41.67. Intercept Pharmaceuticals's number of shares in issue last year was 29.696. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)	=	Gross Profit	/	Revenue
	=	293.539	/	294.522
	=	0.99666239

Gross Margin (Last Year: TTM)	=	Gross Profit	/	Revenue
	=	261.462	/	262.597
	=	0.99567779

Intercept Pharmaceuticals's gross margin of this year was 0.99666239. Intercept Pharmaceuticals's gross margin of last year was 0.99567779. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)	=	Revenue	/	Total Assets at the Beginning of This Year (Mar22)
	=	294.522	/	503.357
	=	0.58511553

Asset Turnover (Last Year)	=	Revenue	/	Total Assets at the Beginning of Last Year (Mar21)
	=	262.597	/	520.111
	=	0.50488646

Intercept Pharmaceuticals's asset turnover of this year was 0.58511553. Intercept Pharmaceuticals's asset turnover of last year was 0.50488646. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score

Que. 1

Que. 2

Que. 3

Que. 4

Que. 5

Que. 6

Que. 7

Que. 8

Que. 9

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Intercept Pharmaceuticals has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Intercept Pharmaceuticals (NAS:ICPT) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.

Intercept Pharmaceuticals Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Intercept Pharmaceuticals's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Intercept Pharmaceuticals (NAS:ICPT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intercept Pharmaceuticals Inc (NAS:ICPT) » Definitions » Piotroski F-Score

Comparable Companies

Traded in Other Exchanges

I4P:Germany

Address

10 Hudson Yards, 37th Floor, New York, NY, USA, 10001

Website

https://www.interceptpharma.com

Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.

Executives

Andrew Saik	officer: EVP & Chief Financial Officer	640 LEE ROAD, CHESTERBROOK PA 19087
M Michelle Berrey	officer: President, R&D and CMO	303A COLLEGE ROAD EAST, PRINCETON NJ 08450
Dagmar Rosa-bjorkeson	director	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Rocco Venezia	officer: Chief Accounting Officer	C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FLOOR, NEW YORK NY 10001
Lisa Defrancesco	officer: SVP, IR & Corp. Affairs	C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, FLOOR 37, NEW YORK NY 10001
Linda M Richardson	officer: EVP & Chief Commercial Officer	2505 MERIDIAN PKWY, SUITE 340, C/O CHIMERIX, INC., DURHAM NC 27713
Jared Freedberg	officer: General Counsel and Secretary	300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Bryan Ball	officer: Chief Quality Officer	300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Paolo Fundaro	director, 10 percent owner	C/O GENEXTRA S.P.A.,, VIA G. DE GRASSI, 11, MILAN L6 20123
Keith Michael Gottesdiener	director	900 FIFTH AVENUE, #8C, NEW YORK NY 10021
Luca Benatti	director	C/O INTERCEPT PHARMACEUTICALS, INC., 450 WEST 15TH STREET, SUITE 505, NEW YORK NY 10011
Daniel G Welch	director	4611 UNIVERSITY DR, 4 UNIVERSITY PLACE, DURHAM NC 27707
Daniel Bradbury	director	BIOBRIT, LLC, 2223 AVENIDA DE LA PLAYA, SUITE 108, LA JOLLA CA 92037
Nancy Miller-rich	director	C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FL, NEW YORK NY 10001
Gino Santini	director	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451